肾病综合征患者血和尿中PAI-1的变化及其临床意义

Alterations of Plasma and Uric PAI-1 in Nephrotic Syndrome Patients

目的探讨肾病综合征患者血、尿PAI-1浓度的改变及其与疾病的关系。方法分为正常对照组、肾病综合征组,采集激素治疗前后血浆和尿液标本用ELISA法检测PAI-1的含量,速率散射比浊法测定尿清蛋白,常规生化方法检测肾功能。结果肾病综合征组血、尿PAI-1含量升高(P<0.05),血浆和尿液中PAI-1与尿清蛋白浓度无明显相关性(r=0.247,0.234,P>0.05),尿液PAI-1和血肌酐值呈正相关(r=0.37,P<0.05)。激素治疗后比治疗前PAI-1水平降低。结论PAI-1在肾病综合征的发生发展中起重要作用。

Objective To measure the plasma and urine levels of plasmimogen activitor inhibitor 1 type（PAI-1）in nephrotic syndrome （NS） patients and to study their clinical significance. Methods Patients were divided into groups of normal control and NS. ELISA was used to measure concentration of PAI-1 in pre-treatment and post-treatment,rate nephelometry was used to detect the M-Alb in urine and clinical chemistry assay was used to measure kidney function. Results The plasma and urine levels of PAI-1 in NS group was significantly higher than that of normal control（P〈0. 05）. There was no significant correlation between levels of PAI-1 and M-Alb in urine and plasma （r=0. 247,0. 234,P〉0.05）,and the urine levels of PAI-1 was positively correlated with degree of the serum creatinine （r=0. 37,P〈0.05）. The concentration of PAI-1 decreased compared to the group of pre-treatment. Conclusion PAI-1 can reflect damage of renal of nephritic syndrome.